Press Releases

Learn more about our products, clinical trial results, and other exciting news.

3/21/2013 - Inspiration Biopharmaceuticals and Ipsen announce closing of the sale of OBI-1 (recombinant porcine factor VIII) to Baxter International

02/19/2013 - Inspiration Biopharmaceuticals and Ipsen announce closing of the IB1001 sale to Cangene Corporation

02/06/2013 - Inspiration Biopharmaceuticals and Ipsen Complete Sale Process for All Hemophilia Assets

01/24/2013 - Inspiration Biopharmaceuticals and Ipsen agree to sell OBI-1 (recombinant porcine factor VIII) to Baxter International for upfront and milestone payments totaling $185 million plus payments on global net sales

11/20/2012 - OBI-1 has received Fast Track designation from FDA for acquired hemophilia A

10/31/2012 - Inspiration Biopharmaceuticals Files for Chapter 11 Protection in Order to Pursue a Broad Strategic Transaction

09/18/2012 - Biopharmaceutical Industry Veterans Join Inspiration Biopharmaceuticals Board of Directors

09/13/2012 - Inspiration Biopharmaceuticals to Present at the UBS Global Life Sciences Conference

08/21/2012 - Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen

08/02/2012 - Inspiration Expands Industry Expertise with Five New Executive Hires

07/10/2012 - Inspiration Announces Clinical Hold of Clinical Trials Evaluating IB1001 for the Treatment and Prevention of Bleeding in Hemophilia B

07/09/2012 - Inspiration Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress

06/27/2012 - Inspiration Presents Data on Porcine Factor VIII Inhibitor Testing Methods at ISTH Meeting

04/17/2012 - Inspiration Files Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B

04/17/2012 - Inspiration Supports World Hemophilia Day 2012 with Activities in Cambridge, MA

02/22/2012 - Inspiration Highlights Positive Data on its rFIX for People with Hemophilia B Who Have Undergone Major Surgical Procedures

12/22/2011 - Inspiration Moves Corporate Headquarters to Cambridge, Massachusetts

12/22/2011 - Inspiration Expands Leadership Team with Four New Hires

12/12/2011 -  Inspiration Presents Key Scientific Data from its Two Lead Hemophilia Development Programs at the 53rd Annual Meeting of the American Society of Hematology (ASH)

11/28/2011 - Inspiration Initiates Second Pivotal Clinical Study of Innovative Hemophilia Therapy OBI-1

10/03/2011 - Inspiration Announces Acceptance of European Marketing Authorization Application for IB1001 for the Treatment of Hemophilia B

09/20/2011 - CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001

08/30/2011 - Inspiration and Ipsen Expand Partnership

07/28/2011 - Inspiration Announces Data from OBI-1 Pivotal-Stage Program in Hemophilia

04/15/2011 - Inspiration Recognizes World Hemophilia Day  - April 17

02/03/2011 - Inspiration Demonstrates Non-Inferiority of IB1001

02/03/2011 - EAHAD 2011 Poster - Pharmacokinetics of IB1001

11/19/2010 - Inspiration Treats First Patient in Pivotal Study of OBI-1 for Acquired Hemophilia A

11/05/2010 - Inspiration Awarded Two Grants Under the Qualifying Therapeutic Discovery Projects Grant Program

11/03/2010 - Inspiration Appoints Karen A. Dawes to the Company's Board of Directors

10/19/2010 - OBI-1 Receives Orphan Drug Designation in Europe

01/21/2010 - Ipsen and Inspiration Enter into Partnership

02/25/2009 - Inspiration Initiates Phase 1 Clinical Trial of IB1001

11/13/2007 - Filing of IND for Novel Recombinant Factor IX Product, IB1001

07/11/2007 - Inspiration Presents At ISTH Annual Meeting